In vivo electroporation improves therapeutic potency of a DNA vaccine targeting hepadnaviral proteins

13Citations
Citations of this article
14Readers
Mendeley users who have this article in their library.

Abstract

This preclinical study investigated the therapeutic efficacy of electroporation (EP)-based delivery of plasmid DNA (pDNA) encoding viral proteins (envelope, core) and IFN-γ in the duck model of chronic hepatitis B virus (DHBV) infection. Importantly, only DNA EP-therapy resulted in a significant decrease in mean viremia titers and in intrahepatic covalently closed circular DNA (cccDNA) levels in chronic DHBV-carrier animals, compared with standard needle pDNA injection (SI). In addition, DNA EP-therapy stimulated in all virus-carriers a humoral response to DHBV preS protein, recognizing a broader range of major antigenic regions, including neutralizing epitopes, compared with SI. DNA EP-therapy led also to significant higher intrahepatic IFN-γ RNA levels in DHBV-carriers compared to other groups, in the absence of adverse effects. We provide the first evidence on DNA EP-therapy benefit in terms of hepadnaviral infection clearance and break of immune tolerance in virus-carriers, supporting its clinical application for chronic hepatitis B. © 2012 Elsevier Inc.

Cite

CITATION STYLE

APA

Khawaja, G., Buronfosse, T., Jamard, C., Abdul, F., Guerret, S., Zoulim, F., … Cova, L. (2012). In vivo electroporation improves therapeutic potency of a DNA vaccine targeting hepadnaviral proteins. Virology, 433(1), 192–202. https://doi.org/10.1016/j.virol.2012.07.014

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free